Tumours cause cells called fibroblasts to stiffen the surrounding tissue so that cancer cells can grip it - allowing them to tunnel through to the blood stream and spread around the body.
Researchers at the Francis Crick Institute and the University of Copenhagen showed that adding experimental drugs reprogrammed fibroblasts - stopping them from 'stiffening' the tissue around tumours.
This healthy tissue trapped the cancer cells, blocking their movement away from the tumour.
The team showed in mice that targeting fibroblasts reduced the movement of cancer cells from the tumour to the lungs and liver through the blood stream.
"It's early days but a very promising new avenue of research. If further studies show this route can benefit patients, it could help crack one of the toughest challenges in cancer research - how to stop tumours spreading," said lead author Janine Erler from Biotech Research and Innovation Centre (BRIC) at the University of Copenhagen.
"The therapy we tested is used to treat inflammatory diseases and could be used to treat cancer patients," said Erler.
The study was published in the journal EMBO Reports.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
